2010可定-重庆-他汀强效降脂的循证历程.ppt.pptVIP

COSMOS研究 214例日本稳定性冠心病患者接受瑞苏伐他汀平均剂量16.9mg/d治疗72周，126例完成IVUS评价 LDL-C平均降低38.6%，P0.0001 HDL-C显著升高19.8%，P0.0001 Apo A1 显著升高17.0%，P0.0001 斑块总体积（TAV）中位数比基线降低5.1%，P0.0001 结论：瑞苏伐他汀显著消退稳定性冠心病患者冠脉斑块体积，可以用于冠心病二级预防 * * * In the pioglitazone group (shown in orange), HDL rose 16% compared with 4.1% for glimepiride (shown in blue) and C-reactive protein fell 44.9% compared with 18%. Triglycerides fell 15.3% with pioglitazone treatment and rose 0.6% with glimepiride treatment. For HDL, CRP and triglycerides, these differences were highly significant, p0.001. LDL cholesterol rose slightly in both groups wit